EXCEL
Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization
Clinical Question
Population
Patients with unprotected left main coronary artery disease and a SYNTAX score of 32 or less at 126 sites in 17 countries.
PCI with everolimus-eluting stents (XIENCE)
Coronary artery bypass grafting (CABG)
Primary Endpoint
Composite of death from any cause, stroke, or myocardial infarction at 3 years (5-year results published in 2019)
Key Findings
At 3 years, the primary endpoint occurred in 15.4% of PCI vs 14.7% of CABG patients (p=0.02 for noninferiority).
At 5 years, the primary endpoint was 22.0% with PCI vs 19.2% with CABG (p=0.13), with no significant difference.
All-cause mortality at 5 years was numerically higher with PCI (13.0% vs 9.9%; p=0.11).
Repeat revascularization was more common with PCI (16.9% vs 10.0%; p<0.001) at 5 years.
Periprocedural MI definitions became a subject of major controversy, with different definitions yielding different conclusions.
Impact on Clinical Practice
Guideline Impact
Limitations
The definition of periprocedural MI was a major source of controversy and may have influenced the primary endpoint results.
Open-label design introduced potential bias in postprocedural management and event ascertainment.
5-year all-cause mortality trended higher with PCI, and longer follow-up showed progressive separation of survival curves favoring CABG.
How Does This Trial Apply to Your Case?
Clinical trials inform guidelines, but every patient is unique. Our Heart Team evaluates how landmark evidence applies to your specific anatomy, risk profile, and preferences.
Send us a messageApply this evidence to your actual case.
Get an independent review from a cardiac surgeon and cardiologist in 24 hours after records are received. No referral needed — pricing is shared on your complimentary discovery call.
Or read how we review cases like this one.
